Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake

Annals of Clinical Biochemistry

Volumn 45, Issue 1, 2008, Pages 93-95

  Le Roux, Carel W ^a   Borg, Cynthia M ^a   Murphy, Kevin G ^a   Vincent, Royce P ^a   Ghatei, Mohammad A ^a   Bloom, Stephen R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE YY [3-36]; PEPTIDE YY; PEPTIDE YY (3 36); UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FOOD INTAKE; HUMAN; MALE; NAUSEA; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; EATING; INTRAVENOUS DRUG ADMINISTRATION;

EATING; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NAUSEA; PEPTIDE YY;

EID: 41649099750     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2007.007068     Document Type: Article

References (7)

1. le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006;147:3-8
2. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985;89:1070-7
3. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005;129:1430-6
4. Greenough A, Cole G, Lewis J, Lockton A, Blundell J. Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion. Physiol Behav 1998;65:303-10
5. Naslund E, King N, Mansten S, et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004;91:439-46
6. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004;20:411-17
7. Wynne KJ, Park A, Bloom SR. Oxyntomodulin causes nausea in high doses. Personal communication, 2005